| Gene symbol | PRDX2 | Synonyms | HEL-S-2a, NKEF-B, NKEFB, PRP, PRX2, PRXII, PTX1, TDPX1, TPX1, TSA | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19p13.13 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | peroxiredoxin 2 | ||||
| GTO ID | GTC3010 |
| Trial ID | NCT05349890 |
| Disease | Epithelial Cancer |
| Altered gene | TSA |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | TSA TCR-T cells |
| Co-treatment | CDX-1140|Pembrolizumab |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) Targeting Patient-unique Tumor-specific Neoantigens, With in Vivo CD40 Activation and PD-1 Blockade, for Patients With Incurable Cancers |
| Year | 2022 |
| Country | United States |
| Company sponsor | Providence Health & Services |
| Other ID(s) | 2021000572 |
| Cohort 1 | |||||||||||
|
|||||||||||